United Therapeutics [UTHR] vs Haleon Plc - ADR [HLN] Detailed Stock Comparison

United Therapeutics Corporation

NASDAQ
Loading...

Haleon Plc - ADR

NYSE
Loading...

TLDR: Quick Comparison Summary

Based on 21 vital metrics comparison: United Therapeutics Corporation wins in 13 metrics, Haleon Plc - ADR wins in 7 metrics, with 0 ties. United Therapeutics Corporation appears stronger overall.

View Metrics Details

Vital Metrics Comparison

Metric United Therapeutics Corporation Haleon Plc - ADR Better
P/E Ratio (TTM) 20.60 18.72 Haleon Plc - ADR
Price-to-Book Ratio 3.53 1.88 Haleon Plc - ADR
Debt-to-Equity Ratio 0.53 52.37 United Therapeutics Corporation
PEG Ratio 0.83 15.42 United Therapeutics Corporation
EV/EBITDA 13.90 33.08 United Therapeutics Corporation
Profit Margin (TTM) 41.94% 15.11% United Therapeutics Corporation
Operating Margin (TTM) 45.23% 23.17% United Therapeutics Corporation
EBITDA Margin (TTM) 45.23% 23.17% United Therapeutics Corporation
Return on Equity 19.72% 10.27% United Therapeutics Corporation
Return on Assets (TTM) 12.44% 4.67% United Therapeutics Corporation
Free Cash Flow (TTM) $1.04B $2.22B Haleon Plc - ADR
Dividend Yield N/A 1.63% N/A
1-Year Return 74.63% -20.18% United Therapeutics Corporation
Price-to-Sales Ratio (TTM) 7.91 3.78 Haleon Plc - ADR
Enterprise Value $22.28B $122.54B Haleon Plc - ADR
EV/Revenue Ratio 7.00 8.23 United Therapeutics Corporation
Gross Profit Margin (TTM) 86.91% 55.38% United Therapeutics Corporation
Revenue per Share (TTM) $72 $2 United Therapeutics Corporation
Earnings per Share (Diluted) $27.88 $0.50 United Therapeutics Corporation
Beta (Stock Volatility) 0.75 0.33 Haleon Plc - ADR
Short % of Float 8.58% 0.43% Haleon Plc - ADR

United Therapeutics Corporation vs Haleon Plc - ADR Stock Performance Analysis

Loading Price Chart...

UTHR
HLN

Performance Comparison

Short-term Returns

Stock1D1W1M3M6MYTD
United Therapeutics Corporation1.74%-6.64%-7.08%5.10%13.90%8.72%
Haleon Plc - ADR0.23%-5.84%-5.84%-19.96%-10.03%-13.00%

Long-term Returns

Stock1Y3Y5Y10Y15Y20Y
United Therapeutics Corporation74.63%156.34%216.46%378.74%788.07%2,079.33%
Haleon Plc - ADR-20.18%9.16%22.27%22.27%22.27%22.27%

Performance & Financial Health Analysis: United Therapeutics Corporation vs Haleon Plc - ADR

MetricUTHRHLN
Market Information
Market Cap i$25.11B$42.40B
Market Cap CategoryLarge capLarge cap
10 Day Avg. Volume i464,4646,594,249
90 Day Avg. Volume i635,8917,985,230
Last Close$549.47$8.72
52 Week Range$272.12 - $609.35$8.65 - $11.30
% from 52W High-9.83%-22.83%
All-Time High$609.35 (May 06, 2026)$11.42 (Jun 02, 2025)
% from All-Time High-9.83%-23.64%
Growth Metrics
Quarterly Revenue Growth0.07%0.01%
Quarterly Earnings Growth0.21%0.86%
Financial Health
Profit Margin (TTM) i0.42%0.15%
Operating Margin (TTM) i0.45%0.23%
Return on Equity (TTM) i0.20%0.10%
Debt to Equity (MRQ) i0.5352.37
Cash & Liquidity
Book Value per Share (MRQ)$162.60$4.99
Cash per Share (MRQ)$66.63$0.15
Operating Cash Flow (TTM) i$1.56B$3.56B
Levered Free Cash Flow (TTM) i$583.20M$1.89B
Dividends
Last 12-Month Dividend Yield iN/A1.63%
Last 12-Month Dividend iN/A$0.17

Valuation & Enterprise Metrics Analysis: United Therapeutics Corporation vs Haleon Plc - ADR

MetricUTHR (Apr 24, 2026)HLN (Apr 24, 2026)
Price Ratios
P/E Ratio (TTM) i20.6018.72
Forward P/E i16.8715.42
PEG Ratio i0.8315.42
Price to Sales (TTM) i7.913.78
Price to Book (MRQ) i3.531.88
Market Capitalization
Market Capitalization i$25.11B$42.40B
Enterprise Value i$22.28B$122.54B
Enterprise Value Metrics
Enterprise to Revenue i7.008.23
Enterprise to EBITDA i13.9033.08
Risk & Other Metrics
Beta i0.750.33
Book Value per Share (MRQ) i$162.60$4.99

Financial Statements Comparison: United Therapeutics Corporation vs Haleon Plc - ADR

Financial Metrics

Loading Financial Charts...

Revenue

Operating Margin

Profit Margin

Long Term Debt

Income Flow Analysis

Financial Statements Comparison

Income Statement

MetricUTHR (2025)HLN (2025)
Revenue/Sales i3.18B11.03B
Cost of Goods Sold i384.40M3.95B
COGS % of Revenue i12.1%35.8%
Gross Profit i2.80B7.08B
Gross Margin i87.9%64.2%
Research & Development i550.00M316.00M
Operating Income (EBIT) i1.52B2.41B
Operating Margin i47.7%21.9%
EBITDA i1.84B2.81B
EBITDA Margin i57.9%25.5%
Pre-Tax Income i1.71B2.15B
Pre-Tax Income % of Revenue i53.9%19.5%
Income Tax i379.20M472.00M
Income Tax % of Revenue i11.9%4.3%
Net Income (Profit) i1.33B1.68B
Profit Margin i41.9%15.2%

Balance Sheet & Liquidity Metrics

MetricUTHR (2025)HLN (2025)
Cash & Equivalents i1.56B1.26B
Total Current Assets i3.70B4.55B
Total Current Assets % of Revenue i116.3%41.3%
Total Current Liabilities i560.60M4.93B
Total Current Liabilities % of Revenue i17.6%44.7%
Long-Term Debt iN/A7.75B
Long-Term Debt % of Revenue i0.0%70.2%
Total Shareholders Equity i7.10B16.48B
Retained Earnings i8.56B27.85B
Retained Earnings % of Revenue i268.9%252.5%
Property, Plant & Equipment i01.00M

Cash Flow Statement Comparison

MetricUTHR (2025)HLN (2025)
Operating Cash Flow i1.44B2.19B
Operating Cash Flow % of Revenue i45.3%19.8%
Capital Expenditures i-520.50M-322.00M
Free Cash Flow i1.04B2.22B
FCF Margin i32.5%20.1%
Debt Repayment i-500.00M-1.35B
Common Stock Repurchase i-1.02B-654.00M

Short Interest & Institutional Ownership Analysis

MetricUTHRHLN
Shares Short i2.84M19.28M
Short Ratio i4.402.14
Short % of Float i8.58%0.43%
Shares Outstanding i43.64M8.91B
Float Shares i40.32M8.86B
% Held by Insiders i1.94%0.01%
% Held by Institutions i97.78%12.74%
% Held by Public i0.28%87.25%

Dividend Analysis & Yield Comparison: United Therapeutics Corporation vs Haleon Plc - ADR

MetricUTHRHLN
Last 12-Month Dividend iN/A$0.17
Last 12-Month Dividend Yield iN/A1.63%
3-Year Avg Annual Dividend iN/A$0.11
3-Year Avg Dividend Yield iN/A0.91%
3-Year Total Dividends iN/A$0.34
Ex-Dividend DateN/AApr 25, 2025